1. Temporary policy on repackaging or combining propofol drug products during the COVID-19 public health emergency Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, Office of Pharmaceutical Quality and Office of Compliance, April 2020 Subject(s): Drug Packaging -- methodsPropofol -- supply & distributionCOVID-19Drug LabelingPharmaciesUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
